Search

Ferns native to Korea, such as Davallia mariesii, Dicranopteris pedata, and Gleichenia japonica, possess antioxidant and antibacterial properties. However, their inhibitory effects on skin photoaging have not been demonstrated. Measurement and comparison of the antioxidant activity of three types of ferns revealed that the extract from G. japonica had the best effect. This study evaluates the potential of G. japonica extract as a new functional material for preventing skin damage caused by ultraviolet radiation. G. japonica extracts showed protective effects against ultraviolet B (UVB) radiation in human epidermal keratinocyte cells; the extracts inhibited intracellular reactive oxygen species production. In addition, collagen biosynthesis increased, and matrix metalloproteinase-1 activity and protein expression level decreased in human primary dermal fibroblast irradiated with UVB. The main peak (compound 1) of the extract was separated through high-performance liquid chromatography analysis and preparative liquid chromatography. Compound 1 is strongly inferred to be the main active ingredient because it showed better antioxidant activity and UVB protection effect than G. japonica extract. These results demonstrate the physiological effects of G. japonica extract and suggest its applicability as a new functional substance for preventing skin damage caused by ultraviolet radiation.

Sarcopenia refers to an age-related reduction of lean body mass. It showed a reciprocal relationship with cardiovascular diseases. Thus, it is imperative to explore pathophysiological mechanisms explaining the relationship between sarcopenia and cardiovascular diseases, along with the clinical assessment, and associated management. In this review, we discuss how processes such as inflammation, oxidative stress, endothelial dysfunction, neural and hormonal modifications, as well as other metabolic disturbances influence sarcopenia as well as its association with cardiovascular diseases. Moreover, this review provides an overview of both non-pharmacological and pharmacological management for patients with sarcopenia and cardiovascular diseases, with a focus on the potential role of cardiovascular drugs to mitigate sarcopenia.

Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent causes of chronic liver disease worldwide which is often seen in patients with metabolic abnormalities such as those with obesity and insulin resistance. On the other hand, sarcopenia is a generalized and progressive skeletal muscle disorder characterized by low muscle strength, low muscle quality, low physical performance, or a combination of the three. Both disease entities share several underlying risk factors and pathophysiologic mechanisms. These include: (1) cardiometabolic overlaps such as insulin resistance, chronic systemic inflammation, decreased vitamin D levels, sex hormone modifications; (2) muscle-related factors such as those mitigated by myostatin signaling, and myokines (i.e., irisin); and (3) liver-dysfunction related factors such as those associated with growth hormone/insulin-like growth factor 1 Axis, hepatokines (i.e., selenoprotein P and leukocyte cell-derived chemotaxin-2), fibroblast growth factors 21 and 19 (FGF21 and FGF19), and hyperammonemia. This narrative review will examine the pathophysiologic overlaps that can explain the links between NAFLD and sarcopenia. Furthermore, this review will explore the emerging roles of nonpharmacologic (e.g., weight reduction, diet, alcohol, and smoking cessation, and physical activity) and pharmacologic management (e.g., roles of β-hydroxy-β-methylbutyrate, branched-chain amino acid supplements, and testosterone therapy) to improve care, intervention sustainability, and acceptability for patients with sarcopenia-associated NAFLD.